NA Proactive news snapshot: Pressure BioSciences, Next Green Wave, Ventura Cannabis and Wellness, Biocept UPDATE … – Proactive Investors USA & Canada

Pressure BioSciences Inc (OTCMKTS:PBIO) announced Thursday that it has won two more customers for its water-soluble CBD manufacturing system, the BaroShear K45. In July, Pressure Bio announced the sale of its first BaroShear K45 system to Nano CBD Cosmetics LLC. The two new orders are from Vancouver-based NanoPeak Solutions Inc and a privately-owned company in Las Vegas, Nevada.

Next Green Wave Holdings Inc (CSE:NGW) (OTCMKTS:NXGWF) hit a new milestone this week with the successful completion of its first cannabis harvest. The Vancouver-based company said Thursday that all 14 flower rooms at the company’s California facility are stocked with plants, and six of them are in the flowering stage. The cannabis company told investors that it expects to become fully operational this month.

Ventura Cannabis and Wellness Corp (CSE:VCAN) has received the stamp of approval from regulators to close its acquisition of Kush Rush, a California dispensary and delivery service. Los Angeles-based Ventura said Thursday that the Bureau of Cannabis Control approved the acquisition, part of Ventura’s strategy to build a network of California dispensaries. Kush Rush will serve as a template for Ventura’s California dispensaries under contract or application, the company said in a statement.

Biocept Inc (NASDAQ:BIOC) announced Thursday it will tout its patented liquid biopsy technology, Target Selector, at a major lung cancer conference in Spain next month.  The San Diego’s company’s Target Selector detects and isolates cancer biomarkers such as circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA). Biocept offers the tests commercially to doctors, hospitals, clinics and researchers, with a focus on lung, breast, gastric, colorectal and prostate cancers as well as melanoma.

Seelos Therapeutics Inc. (NASDAQ:SEEL) revealed Thursday that the US Food and Drug Administration (FDA) has accepted the Investigation New Drug (IND) application for its SLS-005 (trehalose) treatment and has advised

Read More Here...

Leave a Comment

Please Rate This Content*

Your email address will not be published. Required fields are marked *

Scroll to Top